Percutaneous Coronary Interventions in Chronic Total Occlusion - Profile, Technique and Outcome - The Malabar Experience

Follow this and additional works at: https://www.j-saudi-heart.com/jsha

Part of the Cardiology Commons

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Recommended Citation
Vinayakumar, Desabandhu; Raikar, Madhusudan Pramod; and Mohanan, Kurukkanparampil Sreedharan (2020) "Percutaneous Coronary Interventions in Chronic Total Occlusion - Profile, Technique and Outcome - The Malabar Experience," Journal of the Saudi Heart Association: Vol. 32 : Iss. 2 , Article 29. Available at: https://doi.org/10.37616/2212-5043.1082

This Original Article is brought to you for free and open access by Journal of the Saudi Heart Association. It has been accepted for inclusion in Journal of the Saudi Heart Association by an authorized editor of Journal of the Saudi Heart Association.
Percutaneous Coronary Interventions in Chronic Total Occlusion — Profile, Technique and Outcome — The Malabar Experience

Desabandhu Vinayakumar, Madhusudan Pramod Raikar*, Kurukkanparambil Sreedharan Mohanan

Department of Cardiology, Government Medical College, Kozhikode, Kerala 673008, India

Abstract

Introduction: Percutaneous coronary intervention (PCI) of chronic total occlusion (CTO) remains a challenge. The reasons being that these procedures may be lengthy and complex, with elevated radiation exposure, increased contrast load, lower procedural success rate, and a higher risk of complication when compared with non-CTO elective PCI.

Clarifying the long-term clinical outcomes of CTO-PCI is very important to justify potential investments in training and technology. However, there is a paucity of data from Indian subcontinent. Hence we decided to report the outcomes from a real-life cohort of consecutive patients undergoing elective PCI for CTO at our institution.

Materials and methods: Single-center, prospective observational study. A total of 339 consecutive patients who underwent elective PCI for chronic total occlusion between Feb 2016 to Feb 2018 were included in the study. Procedural techniques, complications and clinical outcomes (all-cause death, cardiac death, major adverse cardiac events (MACE) and target vessel revascularization (TVR)) were assessed in our study population.

Results: 339 patients were prospectively followed up for a duration that ranged from 3 months to 36 months, with a median follow up of 24 months. Overall procedural success was achieved in 85.5% (n = 290) cases. No significant differences were noted in In-Hospital adverse events (5.5% vs. 4.1%; p = 0.998). MACE rate was significantly higher in unsuccessful CTO group (36.7% vs. 8.9%, p = 0.001) and was predominantly driven by Ischemia Driven (ID) - Revascularization (16.3% vs. 3.1%, p < 0.001). Cardiac death and All-cause death was not significantly different between the groups. Residual angina (26.5% vs. 10%, p = 0.003) and residual dyspnoea (34.7% vs. 12.4%, p < 0.001) were significantly worse in unsuccessful CTO group.

Conclusions: Procedural success in the present drug-eluting stent (DES) era is more than 80% and newer techniques and hardwares have improved the procedural success rate, especially in younger age groups. MACE rates were significantly higher in the unsuccessful CTO group. Residual angina and dyspnoea were significantly worse in the unsuccessful CTO group.

Keywords: CTO-PCI, Successful CTO-PCI, Microcatheter, MACE, ID-Revascularization

1. Introduction

Percutaneous coronary intervention (PCI) has improved outcomes dramatically in coronary artery disease (CAD) management. But despite being commonly encountered in patients undergoing coronary angiography, percutaneous treatment of chronic total occlusion (CTO) remains a challenge [1,2]. Recanalization of a CTO is attempted in only 10%—15% of patients undergoing percutaneous coronary intervention (PCI) [3]. The reasons being that the CTO PCI procedures may be lengthy and complex, with elevated radiation exposure, increased contrast load, lower procedural success rate, and a higher risk of complication when compared with non-CTO procedures.
elective PCI [4,5]. One other reason is the uncertainty of the prognostic impact of percutaneous CTO revascularization.

Patients with a chronically occluded single-vessel disease (SVD) are often managed medically regardless of the severity of symptoms and extent of ischemia, as the anatomy is deemed to be stable. Whereas, those with multivessel disease (MVD) involving a CTO may be referred for coronary artery bypass graft (CABG) surgery even if other lesions are suitable for PCI [1,6].

Some studies indicate that successful CTO PCI may improve left ventricular function and survival when compared with failed CTO PCI [7–9]. But some studies do not show the benefit [10,11]. Clarifying the long-term clinical outcomes of CTO-PCI is very important to justify potential investments in training and technology, and the potential risks involved. Recently there have been a few studies in DES era which have shown long term benefits on clinical outcomes. However, there is a paucity of data from Indian subcontinent. Hence we decided to report the outcomes from a real-life cohort of consecutive patients undergoing elective PCI for CTO at our institution. This is the first CTO PCI study from northern Kerala traditionally called as Malabar region, after the provincial name of erst while British madras presidency.

2. Materials and Methods

2.1. Study design

A prospective observational study.

2.2. Study setting

Single centre – department of cardiology, Medical College Hospital (MCH), Kozhikode, Kerala, India.

2.3. Study population

A total of 339 consecutive patients who underwent elective PCI for chronic total occlusion between February 2016 to February 2018 were included in the study.

2.4. Inclusion criteria

1. Patients undergoing elective PCI for CTOs in Dept. of cardiology, MCH, Kozhikode.
2. Age ≥18 years and willing to give written informed consent

2.5. Exclusion criteria

1. Patients with an estimated duration of total occlusion less than 3 months

Abbreviations used:

- CTO: chronic total occlusion
- PCI: percutaneous coronary interventions
- MACE: major adverse cardiac events
- TVR: target vessel revascularization
- ID: ischemia driven
- DES: drug eluting stent
- sCTO: successful chronic total occlusion intervention
- uCTO: unsuccessful chronic total occlusion intervention
- ACS: acute coronary syndrome
- UA: unstable angina
- NSTEMI: non ST elevation myocardial infarction
- STEMI: ST elevation myocardial infarction
- CABG: coronary artery bypass grafting
- CIN: contrast induced nephropathy
- LVEF: left ventricular ejection fraction
- HTN: hypertension
- DM: diabetes mellitus
- DLP: dyslipidemia
- CKD: chronic kidney disease
- PAD: peripheral artery disease
- SVD: single vessel disease
- DVD: double vessel disease
- TVD: triple vessel disease
- LM: left main
- EA: effort angina
- AAWMI: anterior wall myocardial infarction
- IWMI: inferior wall myocardial infarction
- LWMI: lateral wall myocardial infarction
- DAPT: dual anti platelet therapy

2. Patients with contraindications for dual antiplatelet therapy (DAPT)
3. Patients with second or third failed attempt of CTO-PCI
4. Patients with end-stage renal disease (ESRD) with eGFR less than 15 ml/kg/m2
5. Patients with incomplete data entry
6. Patients not willing for the study

2.6. End points

1. All cause death
2. Cardiac death
3. Target vessel revascularization (TVR)
4. MACE (composite of non-fatal MI, cardiac death, stroke and need for TVR)

2.7. Follow up

Patients were followed up during the outpatient department (OPD) visits or by a telephonic interview with a minimum follow up of 3 months.

2.8. Statistical analysis

Categorical variables were analyzed using the Pearson's chi-square test when appropriate (expected frequency >5). Otherwise, the Fisher's exact test was used.
Continuous variables were expressed as mean with standard deviation and compared using the independent student t-test.

Time was measured from the first admission for a procedure to an outcome (all-cause mortality).

Significance was inferred at p-value < 0.05.

All the statistical analysis were made using SPSS software (version 10.2, IBM).

2.9. Ethical clearance

The study was approved by the institutional ethical committee (IEC) at government medical college, Kozhikode.

3. Methodology

All the procedures were performed by a single operator.

All patients were pre-treated with aspirin (325 mg) and clopidogrel (300–600 mg).

Only drug-eluting stents were deployed.

The use of GP IIb/IIIa inhibitors was at the discretion of the operator.

Preference of access site, approach to CTO-PCI, use of microcatheter/penetration catheter/cutting balloon and other special techniques was at the discretion of the operator.

After the procedure, all the patients were maintained on DAPT for as long as possible with a minimum of 6 months.

Patient outcomes were stratified according to successful (sCTO) or unsuccessful (uCTO) CTO recanalization.

Patients undergoing an initial unsuccessful procedure but undergoing a subsequent successful attempt were classified as successful.

Data were prospectively entered into a clinical database at the time of the PCI by the performing physician.

Following data was collected:

Patient Characteristics: age, sex, previous acute coronary syndrome (ACS)/PCI/coronary artery bypass grafting (CABG), hypertension, diabetes mellitus, dyslipidemia, peripheral vascular disease, new york heart association (NYHA) functional class, smoking status, chronic renal failure [eGFR between 15 and 90 ml/kg/m2 or on renal replacement therapy], left ventricular function.

Procedure-Related Data: access site, target vessel, number of diseased vessels, approach to CTO-PCI, fluoro time, heparin dose, contrast volume and number of stents deployed.

Procedural Complication Data: access site complications, no/slow flow, side branch occlusion, need for emergency CABG, the incidence of CIN.

Clinical Outcome Data: MACE, cardiac death, all-cause death, need for TVR, residual angina/dyspnoea.

4. Results

CENTRAL ILLUSTRATION:

STUDY POPULATION

n = 339

successful CTO unsuccessful CTO

n = 285 n = 54

successful CTO (on first reattempt) unsuccessful CTO (after first reattempt)

n = 5 n = 49

TOTAL successful CTO

n = 290
4.1. Demographics

A total of 339 patients were followed up for a duration that ranged from a minimum of 3 months to a maximum of 36 months. The median follow-up was 24 months in our study population.

The baseline characteristics of both groups were comparable. The baseline characteristics of our study population are shown in Table 1.

The mean age of our study population was $57.35 \pm 9.17$ overall. The mean age in sCTO group was $57.45 \pm 9.09$ and it was $57.95 \pm 7.57$ in the uCTO group. There was no significant difference between the mean age in both these groups.

However, when we compared different age groups, unsuccessful CTO-PCI was more common in the elderly age group as shown in Table 2 And Fig. 1.

We had more number of males overall in our study group 86.7% (n = 294) compared to females 13.3% (n = 45). Male sex was 84.8% (n = 290) and 97.9% (n = 49) in sCTO and uCTO groups respectively. Though it was statistically significant in uCTO group, it was skewed data since we had very less female patients in our study group.

Both groups were comparable with respect to other baseline demographics.

Patients having effort angina class III-IV were numerically more in uCTO group, but were not statistically significant.

Most of the patients included in our study were having a good baseline LV ejection function. Patients with LV dysfunction (EF < 50%) were numerically more in sCTO group but was not statistically significant.

4.2. Procedural data

Overall successful CTO-PCI was achieved in 85.5% (n = 290) and unsuccessful CTO-PCI was seen in 14.5% (n = 49). Table 3 shows the procedural data of our study population.

### Table 1. Baseline Characteristics

| BASELINE CHARACTERISTICS | sCTO n = 290 (%) | uCTO n = 49 (%) | TOTAL n = 339 (%) | P-value |
|--------------------------|-----------------|-----------------|-------------------|---------|
| AGE (mean ± S.D.)        | 57.45 ± 9.09    | 57.95 ± 7.57    | 57.35 ± 9.17      | 0.716   |
| Male SEX, n (%)          | 246 (84.8)      | 48 (97.9)       | 294 (86.7)        | 0.01    |
| HTN, n (%)               | 161 (55.5)      | 21 (42.8)       | 182 (53.7)        | 0.121   |
| DM, n (%)                | 144 (49.7)      | 24 (48.9)       | 168 (49.5)        | 0.998   |
| DLP, n (%)               | 60 (20.7)       | 9 (18.4)        | 69 (20.3)         | 0.848   |
| SMOKING, n (%)           | 78 (26.9)       | 16 (32.7)       | 94 (27.7)         | 0.487   |
| CKD, n (%)               | 18 (6.2)        | 4 (8.2)         | 22 (6.5)          | 0.539   |
| OBESITY, n (%)           | 34 (11.7)       | 5 (10.2)        | 39 (11.5)         | 0.998   |
| PAD, n (%)               | 11 (3.8)        | 4 (8.2)         | 15 (4.4)          | 0.247   |
| EA III/IV, n (%)         | 102 (35.2)      | 24 (48.9)       | 126 (37.2)        | 0.078   |
| Previous MI, n (%)       | 93 (32.1)       | 19 (38.8)       | 112 (33.0)        | 0.411   |
| AWMI                      | 50 (17.2)       | 6 (12.2)        | 56 (16.5)         | 0.532   |
| IWMI                      | 42 (14.5)       | 13 (26.5)       | 55 (16.2)         | 0.056   |
| LIMI                      | 01 (0.34)       | 0               | 01 (0.29)         | —       |
| Previous ACS, n (%)      | 129 (44.5)      | 20 (40.8)       | 149 (43.9)        | 0.755   |
| UA                        | 6 (1.4)         | 0               | 6 (1.2)           | —       |
| NSTEMI                    | 32 (11.0)       | 1 (2.0)         | 33 (9.7)          | 0.064   |
| STEMI                     | 93 (32.1)       | 19 (38.8)       | 112 (33.0)        | 0.411   |
| Previous PCI, n (%)      | 6 (5.5)         | 0               | 6 (4.7)           | —       |
| Previous CABG, n (%)     | 1 (0.9)         | 0               | 1 (0.8)           | —       |
| LVEF < 50, n (%)         | 44 (15.2)       | 3 (6.1)         | 47 (13.9)         | 0.116   |

Both groups were comparable with respect to other baseline demographics.

Patients having effort angina class III-IV were numerically more in uCTO group, but were not statistically significant.

Most of the patients included in our study were having a good baseline LV ejection function. Patients with LV dysfunction (EF < 50%) were numerically more in sCTO group but was not statistically significant.

### Table 2. Age Wise Distribution Of Procedural Success.

| AGE GROUP | SUCCESS | FAILURE | TOTAL |
|-----------|---------|---------|-------|
| <50       | 52 (91.2) | 05 (8.8) | 57    |
| 50 - 59   | 106 (85.5)| 18 (14.5)| 124   |
| 60 - 69   | 113 (84.3)| 21 (15.7)| 134   |
| ≥70       | 19 (79.1) | 05 (21.9)| 24    |

Fig. 1. Age Wise Distribution Of Procedural Success.
All the study patients underwent viability testing with cardiac magnetic resonance (CMR) imaging, and only patients with significant viable myocardium were included in the study. All the patients underwent PCI through the femoral route. The majority of the cases needed a dual femoral access. However, there was no statistically significant difference in the outcome based on the access used.

Most of the CTO-PCI was performed through the anterograde approach. Only a few were performed through a retrograde approach. Anterograde loose tissue tracking (ALTt) with serial wire escalation was the most common technique used. Anterograde sub-intimal tracking and reentry (ASTR) was used in a few cases. For a retrograde approach, sub-intimal tissue tracking was employed. However, there was no statistically significant difference in relation to the outcome.

Since the serial wire escalation strategy was used, only a few (17%) lesions could be crossed with intermediate wires, and most (83%) lesions required stiff wires.

J-CTO score was calculated to assess the complexity of lesions in all our patients. Mean J-CTO score was 2.05 ± 1.22 in sCTO group & 2.63 ± 1.56 in uCTO group. uCTO group had a higher proportion of patients with worse scores, as depicted in Fig. 2.

In our study, the success rate was higher in the left anterior descending artery (LAD) territory followed by the right coronary artery (RCA) territory. It was lowest in the left circumflex artery (LCX) territory, as shown in Fig. 3. However, the outcomes were not significantly related.

Though procedural success was higher in LAD territory, there were no significant differences in outcome. Fig. 4 shows the success rate in LAD in comparison to other territories.

Special hardware like microcatheter, penetration catheter and cutting balloons were used in most of the cases at operator's discretion. In the remaining cases, only monorail balloon were used. Fig. 5 shows the different hardware used in our study population. However, their use was not statistically significant.

### Table 3. Procedural Data 1.

| Procedural Data | sCTO n = 290 (%) | uCTO n = 49 (%) | TOTAL n = 339 (%) | P-value |
|-----------------|-----------------|----------------|------------------|---------|
| ACCESS SITE, n (%) |                |                |                  |         |
| Femoral         | 84 (28.9)       | 12 (24.5)      | 96 (28.3)        | 0.608   |
| Dual Femoral    | 206 (71.1)      | 37 (75.5)      | 243 (71.7)       |         |
| APPROACH        |                |                |                  | 0.998   |
| Anterograde     | 277 (95.5)      | 47 (95.9)      | 324 (95.6)       |         |
| Retrograde      | 13 (4.5)        | 2 (4.1)        | 15 (4.4)         |         |
| VESSELS INVOLVED |                |                |                  |         |
| SVD             | 145 (50.0)      | 24 (49.0)      | 169 (49.9)       | 0.99    |
| DVD             | 98 (33.8)       | 16 (32.7)      | 114 (33.6)       | 0.870   |
| TVD             | 44 (13.8)       | 8 (16.3)       | 52 (15.3)        | 0.831   |
| LM + SVD        | 1 (0.3)         | 0              | 1 (0.3)          |         |
| LM + DVD        | 1 (0.3)         | 0              | 1 (0.3)          |         |
| LM + TVD        | 2 (0.7)         | 1 (2.0)        | 3 (0.9)          | 0.373   |
| CTO VESSEL      |                |                |                  |         |
| LAD             | 125 (43.1)      | 15 (30.6)      | 140 (41.3)       | 0.117   |
| LCX             | 24 (8.3)        | 7 (14.3)       | 31 (9.1)         | 0.182   |
| RCA             | 117 (40.3)      | 24 (49.0)      | 141 (41.6)       | 0.275   |
| DIAGONAL        | 2 (0.7)         | 0              | 2 (0.6)          |         |
| OM              | 3 (1.0)         | 0              | 3 (0.9)          |         |
| PDA/PLV         | 3 (1.0)         | 0              | 3 (0.9)          |         |
| LAD + LCX       | 5 (0.9)         | 0              | 5 (1.5)          |         |
| LAD + RCA       | 7 (1.8)         | 0              | 7 (2.0)          |         |
| LCX + RCA       | 6 (1.8)         | 3 (6.1)        | 9 (2.6)          | 0.126   |
| MICROCATHERETER USE |            |                |                  |         |
| Fine cross      | 170 (58.6)      | 30 (61.2)      | 200 (58.9)       | 0.756   |
| Corsair         | 8 (2.8)         | 3 (6.1)        | 11 (3.2)         | 0.202   |
| Crusade         | 2 (0.7)         | 1 (2.0)        | 3 (0.9)          | 0.373   |
| Caravel         | 17 (5.8)        | 4 (8.2)        | 21 (6.2)         | 0.522   |
| CUTTING BALLOON USE |        |                |                  |         |
| 2 (0.7)         | 0              | 2 (0.6)        |                 |         |
| ANCHORING BALLOON USE |      |                |                  |         |
| 10 (3.4)        |                | 10 (2.9)       |                 |         |
| BALLOON EMBEDDING IN SIDE BRANCH | 13 (4.5) | 0 | 13 (3.8) |         |
Fluoroscopy time, heparin dose and contrast volume used in our population are tabulated in Table 4. No statistically significant difference was noted between our study groups.

4.3. Complications

Access site complications were the most common procedure-related complications overall. It was significantly more common in uCTO group (8.3% vs. 20.4%; p 0.017). Predominantly driven by TIMI major and minor bleeds.

Other complications like perforation, side branch occlusion, no flow/slow flow, cardiac tamponade, cardiac arrest, contrast-induced nephropathy and need for emergency CABG were seen in only a minority of patients and was not significantly related to the outcome. Table 5 lists the complications encountered in our study groups.

4.4. Clinical outcomes

Our study population had very few in-hospital adverse events, predominately driven by MACE as depicted in Table 6. However, they were not statistically significant.

All cause death and cardiac death were marginally higher in uCTO group but were not statistically significant as shown in Table 7.

New onset ACS was significantly higher in uCTO group (5.5% vs. 14%; p 0.033) which was predominantly driven by non ST-elevation ACS (NSTEMI). ST-elevation myocardial ischemia (STEMI) rates, however were not significantly related to outcomes.

MACE was significantly higher in uCTO group (36.7% vs. 8.9%, p 0.001) and was predominantly driven by Ischemia Driven Revascularization (16.3% vs. 3.1%, p < 0.001).

The need for CABG was significantly higher in uCTO group (16.3% vs. 0.7%, p < 0.001) and was the predominant means of revascularization in uCTO group.
Residual angina (26.5% vs. 10%, p 0.003) and residual dyspnoea (34.7% vs. 12.4%, p < 0.001) were significantly worse in uCTO group.

DAPT was continued beyond 12 months in most of our patients. Only a few patients had discontinued them before 12 months. However, that was not significantly related to the outcomes. Details of the duration of dual antiplatelet therapy is as depicted in Table 8.

5. Discussion

Our study was a single centre, single operator experience in real life in south Indian population.

We had procedural success in 85.5% of patients. A meta-analysis by Patel et al. [13] of 65 studies with 18,061 patients and 18,941 target CTO vessels showed angiographic success in 77%. Few recent studies with the use of modern techniques have shown a procedural success of more than 80% [14,15]. Our results were consistent with these recent studies.

The mean age of our patients was 56.96 ± 9.17. It was observed that procedural success declined as the age advanced (91.2% in <50yrs vs. 79.1% in >70yrs).

We had large male population (86.7%), similar to the extensive UK registry database (78.8% males of 13,443 CTO patients) [16].

Some of the previous studies [17,18] included more patients with older age, lower left ventricular ejection fraction, and previous MI in uCTO group, whereas we did not have any such discrepancy.

Patients with a previous history of revascularization did not have a worse outcome, unlike in previous studies [18].

Patients with worse J-CTO score had poorer outcomes as found in previous studies [15].

We observed that the success rate was 90.3% in LAD territory, whereas it was 81.2% in LCX territory and 84.3% in RCA territory.

Previous studies [19] have reported a significant benefit in survival after successful PCI of a CTO located in the LAD territory but not after successful PCI of a CTO located in the circumflex or right coronary arteries. However, in our study, though procedural success was higher in LAD territory, there was no significant differences in outcome.

Use of special hardwares like micro catheter, penetration catheter and cutting balloon was done in most of the cases and hence led to higher procedural success. However, they were not significantly different among our study groups.

We also noted that fluoroscopy time, heparin dose and contrast volume were marginally higher in uCTO group but was not significant.

Table 4. Procedural Data 2.

|                        | Group | N  | Mean | S.D. |
|------------------------|-------|----|------|------|
| Fluoro Time (min)      | sCTO  | 290| 25.99| 12.64|
|                        | uCTO  | 49 | 27.06| 12.27|
| Heparin Dose (ml)      | sCTO  | 290| 7935.78| 952.82|
|                        | uCTO  | 49 | 7631.58| 573.53|
| Contrast Volume (ml)   | sCTO  | 290| 218.99| 88.07|
|                        | uCTO  | 49 | 218.68| 90.93|

Residual angina (26.5% vs. 10%, p 0.003) and residual dyspnoea (34.7% vs. 12.4%, p < 0.001) were significantly worse in uCTO group.

DAPT was continued beyond 12 months in most of our patients. Only a few patients had discontinued them before 12 months. However, that was not significantly related to the outcomes. Details of the duration of dual antiplatelet therapy is as depicted in Table 8.

5. Discussion

Our study was a single centre, single operator experience in real life in south Indian population.

We had procedural success in 85.5% of patients. A meta-analysis by Patel et al. [13] of 65 studies with 18,061 patients and 18,941 target CTO vessels showed angiographic success in 77%. Few recent studies with the use of modern techniques have shown a procedural success of more than 80% [14,15]. Our results were consistent with these recent studies.

The mean age of our patients was 56.96 ± 9.17. It was observed that procedural success declined as the age advanced (91.2% in <50yrs vs. 79.1% in >70yrs).

We had large male population (86.7%), similar to the extensive UK registry database (78.8% males of 13,443 CTO patients) [16].

Some of the previous studies [17,18] included more patients with older age, lower left ventricular ejection fraction, and previous MI in uCTO group, whereas we did not have any such discrepancy.

Patients with a previous history of revascularization did not have a worse outcome, unlike in previous studies [18].

Patients with worse J-CTO score had poorer outcomes as found in previous studies [15].

We observed that the success rate was 90.3% in LAD territory, whereas it was 81.2% in LCX territory and 84.3% in RCA territory.

Previous studies [19] have reported a significant benefit in survival after successful PCI of a CTO located in the LAD territory but not after successful PCI of a CTO located in the circumflex or right coronary arteries. However, in our study, though procedural success was higher in LAD territory, there was no significant differences in outcome.

Use of special hardwares like micro catheter, penetration catheter and cutting balloon was done in most of the cases and hence led to higher procedural success. However, they were not significantly different among our study groups.

We also noted that fluoroscopy time, heparin dose and contrast volume were marginally higher in uCTO group but was not significant.

Table 5. Complications.

| Complications                        | sCTO n = 290 | uCTO n = 49 | TOTAL n = 339 | P-Value |
|--------------------------------------|--------------|-------------|---------------|---------|
| ACCESS SITE COMPLICATIONS, n (%)     | 24 (8.3)     | 10 (20.4)   | 34 (10.0)     | 0.017   |
| TIMI Minor Bleed                     | 16 (5.5)     | 6 (12.3)    | 22 (6.4)      | 0.108   |
| TIMI Major Bleed                     | 5 (1.7)      | 3 (6.1)     | 8 (2.4)       | 0.093   |
| Pseudoneurysm                        | 3 (1.0)      | 1 (2.0)     | 4 (1.2)       | 0.466   |
| Perforation, n (%)                   | 6 (2.0)      | 3 (6.1)     | 9 (2.7)       | 0.126   |
| Minor                                | 4 (1.3)      | 2 (4.1)     | 6 (1.8)       | 0.209   |
| Major                                | 2 (0.7)      | 1 (2.0)     | 3 (0.9)       | 0.373   |
| Side Branch Occlusion, n (%)         | 4 (1.3)      | 0           | 4 (1.2)       | —       |
| No Flow/Slow Flow, n (%)             | 5 (1.7)      | 0           | 5 (1.5)       | —       |
| Tamponade, n (%)                     | 2 (0.7)      | 1 (2.0)     | 3 (0.9)       | 0.373   |
| Cardiac Arrest, n (%)                | 1 (0.3)      | 0           | 1 (0.3)       | —       |
| Emergency CABG                       | 1 (0.3)      | 0           | 1 (0.3)       | —       |
| CIN, n (%)                           | 9 (3.1)      | 2 (4.1)     | 11 (3.3)      | 0.663   |
Previous studies had postulated that the complications of CTO-PCI might have some influence on the mortality after PCI. Japanese CTO registry showed a coronary perforation rate of 7.2% [15]. Mehran et al. [12] reported the rate of coronary perforation and residual dissection rate of 7.4% and 9.4%, respectively in an unsuccessful CTO group.

In our study, we had a perforation rate of 6.1% in uCTO group though it was not statistically significantly related to outcomes. Access site complications were the most common complication encountered (20.4 vs. 8.3%; p 0.017) and was predominantly driven by TIMI major and minor bleeds.

Severe complications such as cardiac tamponade, cardiac arrest or need for emergency CABG were not significantly different in our study groups. In contrast, they were more frequent in the failed PCI group in previous studies. Olivari et al. [8] reported that 2.3% of patients in the failed CTO-PCI group underwent emergent CABG, but we had none in our study.

Suero et al. [20] reported that the incidence of in-hospital major adverse cardiac events was significantly high in the failed CTO-PCI group but our study did not show any such difference.

Successful CTO-PCI was not associated with a lesser risk for all-cause death and cardiac death over a follow up of 3 yrs unlike previous studies [12]. Probable reasons being, firstly, Subsequent coronary revascularization in uCTO group might have attenuated the possible long-term mortality benefit of successful CTO-PCI. Secondly, the difference in the background characteristics of patients. Because of the relatively high initial success rate, the successful CTO-PCI group included many patients with complex clinical and procedural characteristics, who are deemed to have a poor long-term prognosis. We can postulate that many complex patients

Table 6. In-Hospital Adverse Events.

| In-Hospital Adverse Events | sCTO (n = 290) | uCTO (n = 49) | TOTAL (n = 339) | P-Value |
|----------------------------|----------------|---------------|-----------------|---------|
| Cardiac Death, n (%)       | 0 (0)          | 0 (0)         | 0 (0)           | —       |
| MACE, n (%)                | 16 (5.5)       | 2 (4.1)       | 18 (5.3)        | 0.998   |
| STEMI, n (%)               | 1 (0.3)        | 0 (0)         | 1 (0.3)         | —       |
| Target vessel Re-PCI, n (%)| 1 (0.3)        | 0 (0)         | 1 (0.3)         | —       |

Table 7. Long term clinical outcomes.

| Outcomes                      | sCTO (n = 290) | uCTO (n = 49) | TOTAL (n = 339) | P-Value |
|-------------------------------|----------------|---------------|-----------------|---------|
| All Cause Death, n (%)        | 9 (3.1)        | 3 (6.1)       | 12 (3.5)        | 0.391   |
| Cardiac Death, n (%)          | 6 (2.1)        | 2 (4.1)       | 8 (2.4)         | 0.333   |
| MACE, n (%)                   | 26 (8.9)       | 13 (36.7)     | 39 (11.5)       | 0.001   |
| NEW ACS, n (%)                | 16 (5.5)       | 7 (14.3)      | 23 (6.8)        | 0.033   |
| UA                            | 5 (1.7)        | 2 (4.1)       | 7 (2.1)         | 0.267   |
| NSTEMI                        | 9 (3.1)        | 4 (8.2)       | 13 (3.8)        | 0.102   |
| STEMI                         | 2 (0.7)        | 1 (2.0)       | 3 (0.9)         | 0.373   |
| STEMI, n (%)                  | 2 (0.7)        | 1 (2.0)       | 3 (0.9)         | 0.373   |
| Revascularization, n (%)      | 9 (3.1)        | 8 (16.3)      | 17 (5.0)        | <0.001  |
| Target Vessel Re-PCI, n (%)   | 7 (2.4)        | 0             | 7 (2.1)         | —       |
| Re - PCI, n (%)               | 7 (2.4)        | 0             | 7 (2.1)         | —       |
| CABG, n (%)                   | 2 (0.7)        | 8 (16.3)      | 10 (2.9)        | <0.001  |
| Residual Angina, n (%)        | 29 (10.0)      | 13 (26.5)     | 42 (12.4)       | 0.003   |
| Residual Dyspnoea, n (%)      | 36 (12.4)      | 17 (34.7)     | 53 (15.6)       | <0.001  |

Table 8. Duration Of Dual Antiplatelet Therapy.

| DURATION OF DAPT | sCTO | uCTO | Total | P - value |
|------------------|------|------|-------|-----------|
| LESS THAN 6 MONTHS | 2    | 0    | 2     | —         |
| 6 - 12 MONTHS     | 9    | 1    | 10    | 0.998     |
| MORE THAN 12 MONTHS | 279  | 48   | 329   | 0.998     |
| Total             | 290  | 49   | 339   |           |
included in the sCTO group in our study could be included in the uCTO group in previous studies. Thirdly, a lesser number of procedural complications in uCTO group could have had better long term results.

MACE rate was significantly higher in uCTO group compared to sCTO group (36.7% vs. 8.9%, p 0.001) and was predominantly driven by Ischemia Driven Revascularization (16.3% vs. 3.1%, p < 0.001).

Valenti et al. [17] reported that the incidence of CABG at one year was 9.1% in the failed PCI group. Need for CABG in the uCTO group over a period of 3 yrs 16.3% and was the predominant mode of revascularization in uCTO group.

Successful CTO-PCI had significantly low residual angina(26.5% vs. 10%, p 0.003) and residual dysp-neoa (34.7% vs. 12.4%, p < 0.001).

Most of the patients continued DAPT for more than 12 months. Except for 2 patients who had to discontinue it within 6 months owing to non-cardiac surgery and 10 patients discontinued between 6 and 12 months (6 due to excessive bleeding and 4 defaulters). However, it was not significantly related to outcomes.

There is no randomized controlled trial comparing PCI plus medical therapy with medical therapy alone in patients with CTO. Prospective randomized trials comparing PCI plus medical therapy with medical therapy alone in patients with CTO, adequately powered for evaluating long-term mortality, are absolutely required to define the indication of CTO-PCI.

5.1. Study limitations

Our study was an observational study. Prospective randomized control trials are required to compare PCI plus medical therapy with medical therapy alone to define indications for CTO-PCI. We had a variable duration of follow up, though the median follow up was 24 months. A longer duration of follow up might show better results. Our study was underpowered to evaluate mortality benefits in a successful CTO group. We did not have any angiographic follow up. We did not include a non CTO-PCI comparison group. Hence, we do not know how the outcomes of CTO-PCI group compares with the other non CTO-PCI groups. Unsuccessful CTO group used as a surrogate for medical therapy. A proper comparison with medical therapy alone will be more useful clinically.

6. Conclusions

1. Procedural success in the present drug-eluting stent era is more than 80%, and newer techniques and hardwares have improved the procedural success rates.
2. Successful CTO-PCI was not associated with a lesser risk for all-cause death and cardiac death over a follow up of up to 3 yrs.
3. MACE rates were significantly higher in the unsuccessful CTO-PCI group.
4. Ischemia Driven-Revascularization rates were significantly higher in patients with unsuccessful CTO-PCI.
5. The need for subsequent CABG was very high in the unsuccessful CTO-PCI group.
6. Residual angina and residual dyspnoea were significantly worse in the unsuccessful CTO-PCI group.

Author contribution

Desabandhu Vinayakumar, Mohanan K. S: Conceptualization of study, Intermittent review of data collected.

Desabandhu Vinayakumar, Raikar M. P., Mohanan K. S.: Study design and expected results, Critical review of article.

Raikar M. P.: Collection and tabulation of data.

Raikar M. P., Mohanan K. S.: Analysis of data, Review of past literature.

Desabandhu Vinayakumar, Raikar M. P.: Write up of the article.

Ethical Clearance

The study was approved by institutional ethical committee (IEC) at government medical college, Kozhikode.

Conflicts of Interest

All authors declared there is no conflicts of interest in this study and there is no grant and financial support to this study.

References

[1] Christofferson RD, Lehmann KG, Martin GV, Every N, Caldwell JH, Kapadia SR. Effect of chronic total coronary occlusion on treatment strategy. Am J Cardiol 2005;95(9): 1088–91. https://doi.org/10.1016/j.amjcard.2004.12.065.

[2] Cohen HA, Williams DO, Holmes Jr DR, et al. Impact of age on procedural and 1-year outcome in percutaneous trans-luminal coronary angioplasty: a report from the NHLBI Dynamic Registry. Am Heart J 2003;146(3):513–9. https://doi.org/10.1016/S0002-8703(03)00259-X.

[3] Grantham JA, Marso SP, Sprott J, House J, Holmes Jr DR, Rutherford BD. Chronic total occlusion angioplasty in the
Lee SW, Lee JY, Park DW, et al. Long-term clinical outcomes of percutaneous coronary artery occlusions: what does it cost in radiation exposure, time, and materials? Cathet Cardiovasc Diagn 1992;25(1):10–5. https://doi.org/10.1002/crd.1810250104.

Suzuki S, Furui S, Kohtake H, et al. Radiation exposure to patient’s skin during percutaneous coronary intervention for various lesions, including chronic total occlusion. Circ J 2006;70(1):44–8. https://doi.org/10.1253/circj.70.44.

Srinivas VS, Brooks MM, Detre KM, et al. Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: a comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study. Circulation 2002;106(13):1627–33. https://doi.org/10.1161/01.cir.0000031570.27023.79.

Joyal D, Aflalo J, Rin fret S. Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis. Am Heart J 2010;160(1):179–87. https://doi.org/10.1016/j.ahj.2010.04.015.

Olivari Z, Rubartelli P, Piscione F, et al. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE). J Am Coll Cardiol 2003;41(10):1672–8. https://doi.org/10.1016/s0735-1097(03)00312-7.

Sirnes PA, Myrenge Y, Molstad P, Bonarjee V, Golf S. Improvement in left ventricular ejection fraction and wall motion after successful recanalization of chronic coronary occlusions. Eur Heart J 1998;19(2):273–81. https://doi.org/10.1053/euhj.1997.0617.

Lee SW, Lee JY, Park DW, et al. Long-term clinical outcomes of successful versus unsuccessful revascularization with drug-eluting stents for true chronic total occlusion. Catheter Cardiovasc Interv 2011;78(3):346–53. https://doi.org/10.1002/ccd.23019.

Prasad A, Rihal CS, Lennon RJ, Wiste HJ, Singh M, Holmes Jr DR. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol 2007;49(15):1611–8. https://doi.org/10.1016/j.jacc.2006.12.040.

Mehran R, Claessen BE, Godino C, et al. Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv 2011;4(9):952–61. https://doi.org/10.1016/j.jcin.2011.03.021.

Patel VG, Brayton KM, Tamayo A, et al. Angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: a weighted meta-analysis of 18,061 patients from 65 studies. JACC Cardiovasc Interv 2013;6(2):128–36. https://doi.org/10.1016/j.jcin.2012.10.011.

Galassi AR, Tomasello SD, Reifart N, et al. In-hospital outcomes of percutaneous coronary intervention in patients with chronic total occlusion: insights from the ERCTO (European Registry of Chronic Total Occlusion) registry. EuroIntervention 2011;7(4):472–9. https://doi.org/10.4244/EIJV7I4A77.

Morino Y, Kimura T, Hayashi Y, et al. In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan). JACC Cardiovasc Interv 2010;3(2):143–51. https://doi.org/10.1016/j.jcin.2009.10.029.

George S, Cockburn J, Clayton TC, et al. Long-term follow-up of elective chronic total coronary occlusion angioplasty: analysis from the U.K. Central Cardiac Audit Database [published correction appears in J Am Coll Cardiol. 2014 Oct 7;64(14):1538]. J Am Coll Cardiol 2014;64(3):235–43. https://doi.org/10.1016/j.jacc.2014.04.040.

Valenti R, Migliorini A, Signorini U, et al. Impact of complete revascularization with percutaneous coronary intervention on survival in patients with at least one chronic total occlusion. Eur Heart J 2008;29(19):2336–42. https://doi.org/10.1093/eurheartj/ehn357.

Jones DA, Weerackody R, Rathod K, et al. Successful recanalization of chronic total occlusions is associated with improved long-term survival. JACC Cardiovasc Interv 2012;5(4):380–8. https://doi.org/10.1016/j.jcin.2012.01.012.

Sailey DM, House JA, Marso SP, Grantham JA, Rutherford BD. Improvement in survival following successful percutaneous coronary intervention of chronic total occlusions: variability by target vessel. JACC Cardiovasc Interv 2008;1(3):295–302. https://doi.org/10.1016/j.jcin.2008.05.004.

Suero JA, Marso SP, Jones PG, et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol 2001;38(2):409–14. https://doi.org/10.1016/s0735-1097(01)01349-3.